Literature DB >> 11559476

Treatment-refractory schizophrenia.

P F Buckley1, L D Wiggins, S Sebastian, B Singer.   

Abstract

Treatment-refractory schizophrenia is common. Refinements in pharmacologic and psychosocial treatments of schizophrenia offer the expectation of superior outcomes for this disadvantaged patient group. This article critically reviews those articles that were published during the year 2000 that address this treatment-refractory population.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11559476     DOI： 10.1007/s11920-996-0033-z

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN： 1523-3812            Impact factor:   5.285


  63 in total

1.  Combined electroconvulsive-clozapine therapy.

Authors:  M Kupchik; B Spivak; R Mester; I Reznik; N Gonen; A Weizman; M Kotler
Journal:  Clin Neuropharmacol       Date:  2000 Jan-Feb       Impact factor: 1.592

2.  Treatment refractory schizophrenia.

Authors:  J P Lindenmayer
Journal:  Psychiatr Q       Date:  2000

3.  Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. The Quebec Schizophrenia Study Group.

Authors:  R H Bouchard; C Mérette; E Pourcher; M F Demers; J Villeneuve; M H Roy-Gagnon; Y Gauthier; D Cliche; A Labelle; M J Filteau; M A Roy; M Maziade
Journal:  J Clin Psychopharmacol       Date:  2000-06       Impact factor: 3.153

4.  QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients.

Authors:  J G Reilly; S A Ayis; I N Ferrier; S J Jones; S H Thomas
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

5.  Risperidone use at a state hospital: a clinical audit 2 years after the first wave of risperidone prescriptions.

Authors:  K N Chengappa; S Sheth; J S Brar; H Parepally; S Marcus; A Gopalani; A Palmer; R W Baker; N R Schooler
Journal:  J Clin Psychiatry       Date:  1999-06       Impact factor: 4.384

6.  Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life.

Authors:  L Voruganti; L Cortese; L Oyewumi; Z Cernovsky; S Zirul; A Awad
Journal:  Schizophr Res       Date:  2000-06-16       Impact factor: 4.939

7.  The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.

Authors:  R S Keefe; S G Silva; D O Perkins; J A Lieberman
Journal:  Schizophr Bull       Date:  1999       Impact factor: 9.306

Review 8.  Cognitive-behavioral therapy for medication-resistant symptoms.

Authors:  P A Garety; D Fowler; E Kuipers
Journal:  Schizophr Bull       Date:  2000       Impact factor: 9.306

9.  Comparison of cost, dosage and clinical preference for risperidone and olanzapine.

Authors:  J Rabinowitz; P Lichtenberg; Z Kaplan
Journal:  Schizophr Res       Date:  2000-12-15       Impact factor: 4.939

10.  Alteration in the recommended dosing schedule for risperidone.

Authors:  D J Luchins; D Klass; P Hanrahan; R Malan; J Harris
Journal:  Am J Psychiatry       Date:  1998-03       Impact factor: 18.112
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.